Company profile: Sapiens
1.1 - Company Overview
Company description
- Provider of medical device solutions for deep brain stimulation (DBS) therapy, developing a unique, high-resolution, MRI-compatible DBS system intended to improve patient comfort and therapeutic outcomes.
Products and services
🔒
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Sapiens
AxoGen
HQ: United States
Website
- Description: Provider of treatment options for peripheral nerve reconstruction and repair, offering Avance® Nerve Graft to bridge nerve discontinuities and facilitate regeneration, Axoguard Nerve Cap® to protect and isolate nerve ends to reduce neuroma formation, Axoguard® Nerve Connector for tensionless coaptation, and Axoguard® Nerve Protector to prevent soft tissue attachments and support nerve healing.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full AxoGen company profile →
Tryp Therapeutics
HQ: Canada
Website
- Description: Provider of clinical-stage psilocybin-based therapeutics, developing an IV infusion of psilocin and synthetic oral psilocybin to address neuropsychiatric disorders, orphan diseases, and conditions with no effective first-line treatments. Offerings include TRP-8803, a proprietary IV psilocin formulation, TRP-8802 in early-stage trials, and Phase 2a studies in fibromyalgia, binge eating disorder, and irritable bowel syndrome.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Tryp Therapeutics company profile →
Blockade Medical
HQ: United States
Website
- Description: Provider of catheter-based therapeutic devices for the treatment of cerebral aneurysms. Founded in 2011, Blockade Medical is a privately held company with a management team totaling 65+ years in the neurovascular field, committed to bringing products to market that are current standards of care.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Blockade Medical company profile →
PaxMedica
HQ: United States
Website
- Description: Provider of biopharmaceutical therapies addressing neurodevelopmental disorders, including PAX-101 for early-stage East African Human African Trypanosomiasis and PAX-101 under development for Autism Spectrum Disorder. Conducts clinical trials evaluating suramin in ASD and collaborates on translational research to support research leading to FDA-approved treatments for autism comorbidities.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full PaxMedica company profile →
Torrey Pines Therapeutics
HQ: United States
Website
- Description: Provider of small molecule drug discovery and development in the United States, with a portfolio comprising candidates from proprietary drug-targeting platforms and in-licensed/acquired programs. As of August 31, 2010, the company's pipeline includes three clinical development programs.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Torrey Pines Therapeutics company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Sapiens
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Sapiens
2.2 - Growth funds investing in similar companies to Sapiens
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Sapiens
4.2 - Public trading comparable groups for Sapiens
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →